Why Is Planet Labs Stock Up Today?
Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…
Sell
36
OMER Quote, Financials, Valuation and Earnings
Last price:
$3.19
Seasonality move
:
6.92%
Day range:
$3.26 - $3.51
52-week range:
$2.97 - $13.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
867.1K
Avg. volume:
1M
1-year change:
-13.09%
Market cap:
$194.5M
Revenue:
--
EPS (TTM):
-$2.65
Analysts' Opinion
-
Consensus RatingOmeros has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.50, Omeros has an estimated upside of 577.71% from its current price of $3.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $3.32.
Fair Value
-
According to the consensus of 3 analysts, Omeros has 577.71% upside to fair value with a price target of $22.50 per share.
OMER vs. S&P 500
-
Over the past 5 trading days, Omeros has overperformed the S&P 500 by 0.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Omeros does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Omeros has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Omeros reported revenues of --.
Earnings Growth
-
Omeros has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Omeros reported earnings per share of -$0.58.
Enterprise value:
328M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-2.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$164.1M | -$167.9M | -$165.2M | -$39M | -$35M | |
| EBITDA | -$155.7M | -$147M | -$155.2M | -$35.4M | -$33.6M | |
| Diluted EPS | $0.74 | -$1.97 | -$2.65 | -$0.63 | -$0.58 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.5M | $210.2M | $417M | $281M | $96.2M | |
| Total Assets | $161.4M | $369.3M | $560.1M | $437.5M | $235.2M | |
| Current Liabilities | $43.4M | $35.1M | $139.2M | $59.1M | $83.2M | |
| Total Liabilities | $383.4M | $374.2M | $505.2M | $508.8M | $448.7M | |
| Total Equity | -$222M | -$4.9M | $54.9M | -$71.3M | -$213.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $103.2M | -$141.6M | -$142.9M | -$41.8M | -$35.8M | |
| Cash From Investing | -$232.1M | $146.9M | $182.7M | -$61.9M | $38.5M | |
| Cash From Financing | $123.7M | -$7.3M | -$37.4M | $98.4M | -$1.8M | |
| Free Cash Flow | $103.1M | -$142.1M | -$143M | -$41.8M | -$35.9M | |
OMER
Sector
Market Cap
$194.5M
$33.7M
Price % of 52-Week High
24.41%
47.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
-13.09%
-35.46%
Beta (5-Year)
2.199
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.30
200-day SMA
Sell
Level
$6.62
Bollinger Bands (100)
Sell
Level
4.21 - 8.75
Chaikin Money Flow
Sell
Level
-51.8M
20-day SMA
Sell
Level
$3.38
Relative Strength Index (RSI14)
Sell
Level
39.89
ADX Line
Sell
Level
28.21
Williams %R
Neutral
Level
-77.5574
50-day SMA
Sell
Level
$4.66
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
59.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Stock Forecast FAQ
In the current month, OMER has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The OMER average analyst price target in the past 3 months is $22.50.
-
Where Will Omeros Stock Be In 1 Year?
According to analysts, the consensus estimate is that Omeros share price will rise to $22.50 per share over the next 12 months.
-
What Do Analysts Say About Omeros?
Analysts are divided on their view about Omeros share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Omeros is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Omeros's Price Target?
The price target for Omeros over the next 1-year time period is forecast to be $22.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is OMER A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Omeros is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of OMER?
You can purchase shares of Omeros via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Omeros shares.
-
What Is The Omeros Share Price Today?
Omeros was last trading at $3.19 per share. This represents the most recent stock quote for Omeros. Yesterday, Omeros closed at $3.32 per share.
-
How To Buy Omeros Stock Online?
In order to purchase Omeros stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Coherent Stock Breaking Out?
Coherent (NYSE: COHR) has spent the better part of two years…
What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
95
AVAV alert for Jun 27
AeroVironment [AVAV] is up 2.13% over the past day.
Buy
70
AEVA alert for Jun 27
Aeva Technologies [AEVA] is up 8.52% over the past day.
Buy
88
TSSI alert for Jun 27
TSS [TSSI] is down 2.73% over the past day.
